Martin Dunbar
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 23
- Hematology top 0.5%
- Acute Myeloid Leukemia Research 8
- Chronic Myeloid Leukemia Treatments 8
- Multiple Myeloma Research and Treatments 7
-
- Lymphoma Diagnosis and Treatment 12
- Oncology top 2%
- PARP inhibition in cancer therapy 11
- Cancer Treatment and Pharmacology 8
- Immunology top 5%
-
- Lung Cancer Treatments and Mutations 8
Martin Dunbar
66 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 145
- Genetics 1.5k
- Hematology 1.4k
- Pathology and Forensic Medicine 957
- Oncology 1.1k
- Immunology 453
Countries citing papers authored by Martin Dunbar
This map shows the geographic impact of Martin Dunbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Dunbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Dunbar more than expected).
Fields of papers citing papers by Martin Dunbar
This network shows the impact of papers produced by Martin Dunbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Dunbar. The network helps show where Martin Dunbar may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Martin Dunbar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 19 | |
| 5 | 2021 | 52 | |
| 6 | 2019 | 39 | |
| 7 | 2018 | 51 | |
| 8 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studybreakdown → | 2018 | 498 |
| 9 | 2017 | 12 | |
| 10 | 2017 | 4 | |
| 11 | 2016 | 25 | |
| 12 | 2016 | 77 | |
| 13 | 2015 | 75 | |
| 14 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemiabreakdown → | 2015 | 1337 |
| 15 | 2015 | 60 | |
| 16 | 2014 | 50 | |
| 17 | 2009 | 60 | |
| 18 | 2000 | 145 | |
| 19 | 1997 | 45 | |
| 20 | 1995 | 43 |
About Martin Dunbar
Martin Dunbar is a scholar working on Genetics, Hematology and Oncology, having authored 68 papers that have together received 4.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (23 papers), Lymphoma Diagnosis and Treatment (12 papers), PARP inhibition in cancer therapy (11 papers), Lung Cancer Treatments and Mutations (8 papers), Acute Myeloid Leukemia Research (8 papers), Cancer Treatment and Pharmacology (8 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Multiple Myeloma Research and Treatments (7 papers). The work is most often cited by research in Genetics (1.5k citations), Hematology (1.4k citations) and Pathology and Forensic Medicine (957 citations). Martin Dunbar has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Rod Humerickhouse, Shekman Wong, Suresh Agarwal, Ming Zhu, Sari H. Enschede, John M. Pagel, Brad S. Kahl, John F. Gerecitano, Andrew W. Roberts and Matthew S. Davids. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.